{"id":12335,"date":"2025-10-10T23:36:13","date_gmt":"2025-10-10T16:36:13","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=12335"},"modified":"2025-10-10T23:36:13","modified_gmt":"2025-10-10T16:36:13","slug":"escitalopram","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/escitalopram\/","title":{"rendered":"Escitalopram"},"content":{"rendered":"

(Ph. Eur. monograph 2758)<\/p>\n

C_{20<\/sub>H_{21<\/sub>FN_{2<\/sub>O 324.4 128196-01-0Escitalopram<\/p>\n}}}

Action and use<\/strong><\/p>\n

Selective serotonin reuptake inhibitor; antidepressant.<\/p>\n

DEFINITION<\/h2>\n
(1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile.<\/p>\n
Content<\/h3>\n
99.0 per cent to 101.0 per cent (anhydrous substance).<\/p>\n
CHARACTERS<\/h2>\n
Appearance<\/h3>\n
White or yellowish, crystalline powder.<\/p>\n
Solubility<\/h3>\n
Practically insoluble in water, freely soluble in anhydrous ethanol and in toluene.<\/p>\n
IDENTIFICATION<\/h2>\n
A. Infrared absorption spectrophotometry (2.2.24).<\/p>\n
Comparison escitalopram CRS.<\/p>\n
B. Enantiomeric purity (see Tests).<\/p>\n
TESTS<\/h2>\n
Related substances<\/h3>\n
Liquid chromatography (2.2.29).<\/p>\n
Buffer solution: Dissolve 3.4 g of potassium dihydrogen phosphate R in 900 mL of water R; adjust to pH 3.0 with phosphoric acid R and dilute to 1000 mL with water R.<\/p>\n
Test solution: Dissolve 25 mg of the substance to be examined in mobile phase A and dilute to 50.0 mL with mobile phase A.<\/p>\n
Reference solution (a): Dissolve 5 mg of escitalopram for system suitability CRS (containing impurity D) in mobile phase A and dilute to 10.0 mL with mobile phase A.<\/p>\n
Reference solution (b): Dilute 1.0 mL of the test solution to 100.0 mL with mobile phase A. Dilute 1.0 mL of this solution to 10.0 mL with mobile phase A.<\/p>\n
Column:<\/p>\n
\u2014 size: l = 0.25 m, \u00d8 = 4.6 mm;<\/p>\n
\u2014 stationary phase: end-capped octadecylsilyl silica gel for chromatography R (5 \u03bcm);<\/p>\n
\u2014 temperature: 45 \u00b0C.<\/p>\n
Mobile phase:<\/p>\n
\u2014 mobile phase A: acetonitrile R, buffer solution (10:90 V\/V);<\/p>\n
\u2014 mobile phase B: buffer solution, acetonitrile R (35:65 V\/V);<\/p>\n\n\n\n\n\n\n\n
Time
\n(min)<\/td>\n Mobile phase A
\n(per cent V\/V)<\/td>\n Mobile phase B
\n(per cent V\/V)<\/td>\n Flow rate
\n(mL\/min)<\/td>\n<\/tr>\n
0 – 2<\/td>\n 95<\/td>\n 5<\/td>\n 1.0<\/td>\n<\/tr>\n
2 – 37<\/td>\n 95 \u2192 65<\/td>\n 5 \u2192 35<\/td>\n 1.0<\/td>\n<\/tr>\n
37 – 47<\/td>\n 65 \u2192 0<\/td>\n 35 \u2192 100<\/td>\n 1.0<\/td>\n<\/tr>\n
47 – 62<\/td>\n 0<\/td>\n 100<\/td>\n 2.0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Detection: Spectrophotometer at 237 nm and at 254 nm.<\/p>\n
Injection 20 \u03bcL.<\/p>\n
Identification of impurities: Use the chromatogram supplied with escitalopram for system suitability CRS and the chromatogram obtained with reference solution (a) to identify the peak due to impurity D.<\/p>\n
Relative retention: With reference to escitalopram (retention time = about 38 min): impurity D = about 0.98.<\/p>\n
System suitability Reference solution (a) at 237 nm:<\/p>\n
\u2014 peak-to-valley ratio: minimum 5.0, where Hp = height above the baseline of the peak due to impurity D and Hv = height above the baseline of the lowest point of the curve separating this peak from the peak due to escitalopram.<\/p>\n
Calculation of percentage contents:<\/p>\n
\u2014 for each impurity, use the concentration of escitalopram in reference solution (b) at 237 nm.<\/p>\n
Limits:<\/p>\n
\u2014 unspecified impurities at 237 nm and at 254 nm: for each impurity, maximum 0.10 per cent;<\/p>\n
\u2014 total at 237 nm: maximum 0.5 per cent;<\/p>\n
\u2014 reporting threshold at 237 nm: 0.05 per cent.<\/p>\n
Enantiomeric purity<\/h3>\n
Liquid chromatography (2.2.29): use the normalisation procedure.<\/p>\n
Test solution: Dissolve 25.0 mg of the substance to be examined in the mobile phase and dilute to 50.0 mL with the mobile phase. Dilute 5.0 mL of the solution to 20.0 mL with the mobile phase.<\/p>\n
Reference solution (a): Dissolve 5.0 mg of citalopram hydrobromide CRS (containing equal amounts of impurity K and escitalopram) in the mobile phase and dilute to 10.0 mL with the mobile phase. Dilute 5.0 mL of the solution to 20.0 mL with the mobile phase.<\/p>\n
Reference solution (b): Dilute 1.0 mL of reference solution (a) to 50.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.<\/p>\n
Column:<\/p>\n
\u2014 size: l = 0.15 m, \u00d8 = 4.6 mm;<\/p>\n
\u2014 stationary phase: protein derivative of silica gel for chiral separation R (5 \u03bcm);<\/p>\n
\u2014 temperature: 30 \u00b0C.<\/p>\n
Mobile phase acetonitrile R, 0.05 M phosphate buffer solution pH 7.0 R (15:85 V\/V).<\/p>\n
Flow rate 0.6 mL\/min.<\/p>\n
Detection: Spectrophotometer at 240 nm.<\/p>\n
Injection 15 \u03bcL.<\/p>\n
Run time Twice the retention time of escitalopram.<\/p>\n
Identification of impurities: Use the chromatogram obtained with reference solution (a) to identify the peak due to impurity K.<\/p>\n
Relative retention With reference to escitalopram (retention time = about 11 min): impurity K = about 1.2.<\/p>\n
System suitability Reference solution (a):<\/p>\n
\u2014 resolution: minimum 1.3 between the peaks due to escitalopram and impurity K;<\/p>\n
\u2014 symmetry factor: maximum 4.0 for the peak due to escitalopram; maximum 4.0 for the peak due to impurity K.<\/p>\n
Limits:<\/p>\n
\u2014 impurity K: maximum 2.0 per cent;<\/p>\n
\u2014 reporting threshold: 0.10 per cent (reference solution (b)).<\/p>\n
Water (2.5.12)<\/h4>\n
Maximum 0.2 per cent, determined on 0.500 g.<\/p>\n
Sulfated ash (2.4.14)<\/h4>\n
Maximum 0.1 per cent, determined on 1.0 g in a platinum crucible.<\/p>\n
ASSAY<\/h2>\n
Dissolve 0.300 g in a mixture of 5.0 mL of acetic anhydride R and 75 mL of glacial acetic acid R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20).<\/p>\n
1 mL of 0.1 M perchloric acid is equivalent to 32.44 mg of C_{20<\/sub>H_{21<\/sub>FN_{2<\/sub>O.<\/p>\n}}}
IMPURITIES<\/h2>\n
Specified impurities K.<\/p>\n
Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) A, B, C, D, E, F, G, H, I, J, L, M.<\/p>\n
$\"Escitalopram\"$ <\/p>\n
A. (1RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carboxamide,<\/p>\n
$\"Escitalopram\"$ <\/p>\n
B. mixture of (1RS,3RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydro-2-benzofuran-5-carbonitrile and (1RS,3SR)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydro-2-benzofuran-5-carbonitrile,<\/p>\n
$\"Escitalopram\"$ <\/p>\n
C. (1RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-oxo-1,3-dihydro-2-benzofuran-5-carbonitrile,<\/p>\n
$\"Escitalopram\"$ <\/p>\n
D. (1RS)-1-(4-fluorophenyl)-1-[3-(methylamino)propyl]-1,3-dihydro-2-benzofuran-5-carbonitrile,<\/p>\n
$\"Escitalopram\"$ <\/p>\n
E. (4RS)-4-[4-cyano-2-(hydroxymethyl)phenyl]-4-(4-fluorophenyl)-4-hydroxy-N,N-dimethylbutan-1-aminium,<\/p>\n
$\"Escitalopram\"$ <\/p>\n
F. (1RS)-1-[3-(dimethylamino)propyl]-1-hydroxy-1,3-dihydro-2-benzofuran-5-carbonitrile,<\/p>\n
$\"Escitalopram\"$ <\/p>\n
G. 4-(dimethylamino)-1-[(1RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-yl]butan-1-one,<\/p>\n
$\"Escitalopram\"$ <\/p>\n
H. 3-[(1RS)-5-cyano-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-1-yl]-N,N-dimethylpropan-1-amine N-oxide,<\/p>\n
$\"Escitalopram\"$ <\/p>\n
I. 4-[(1Z)-4-(dimethylamino)-1-(4-fluorophenyl)but-1-en-1-yl]-3-(hydroxymethyl)benzonitrile,<\/p>\n
$\"Escitalopram\"$ <\/p>\n
J. 4-methylbenzenesulfonic acid (p-toluenesulfonic acid),<\/p>\n
$\"Escitalopram\"$ <\/p>\n
K. (1R)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile,<\/p>\n
$\"Escitalopram\"$ <\/p>\n
L. (1RS)-1-[3-(dimethylamino)propyl]-1-phenyl-1,3-dihydro-2-benzofuran-5-carbonitrile,<\/p>\n
$\"Escitalopram\"$ <\/p>\n
M. (1RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carboxylic acid.<\/p>\n","protected":false},"excerpt":{"rendered":"
(Ph. Eur. monograph 2758) C20H21FN2O 324.4 128196-01-0Escitalopram Action and use Selective serotonin reuptake inhibitor; antidepressant. DEFINITION (1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile. Content 99.0 per cent to 101.0 per cent (anhydrous substance). CHARACTERS Appearance White or yellowish, crystalline powder. Solubility Practically insoluble in water, freely soluble in anhydrous ethanol and in toluene. IDENTIFICATION A. Infrared absorption spectrophotometry (2.2.24). Comparison escitalopram…<\/p>\n","protected":false},"author":2,"featured_media":12373,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-12335","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/12335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=12335"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/12335\/revisions"}],"predecessor-version":[{"id":12375,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/12335\/revisions\/12375"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/12373"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=12335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=12335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=12335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Time \n(min)<\/td>\n	Mobile phase A \n(per cent V\/V)<\/td>\n	Mobile phase B \n(per cent V\/V)<\/td>\n	Flow rate \n(mL\/min)<\/td>\n<\/tr>\n
0 – 2<\/td>\n	95<\/td>\n	5<\/td>\n	1.0<\/td>\n<\/tr>\n
2 – 37<\/td>\n	95 \u2192 65<\/td>\n	5 \u2192 35<\/td>\n	1.0<\/td>\n<\/tr>\n
37 – 47<\/td>\n	65 \u2192 0<\/td>\n	35 \u2192 100<\/td>\n	1.0<\/td>\n<\/tr>\n
47 – 62<\/td>\n	0<\/td>\n	100<\/td>\n	2.0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Detection: Spectrophotometer at 237 nm and at 254 nm.<\/p>\n Injection 20 \u03bcL.<\/p>\n Identification of impurities: Use the chromatogram supplied with escitalopram for system suitability CRS and the chromatogram obtained with reference solution (a) to identify the peak due to impurity D.<\/p>\n Relative retention: With reference to escitalopram (retention time = about 38 min): impurity D = about 0.98.<\/p>\n System suitability Reference solution (a) at 237 nm:<\/p>\n \u2014 peak-to-valley ratio: minimum 5.0, where Hp = height above the baseline of the peak due to impurity D and Hv = height above the baseline of the lowest point of the curve separating this peak from the peak due to escitalopram.<\/p>\n Calculation of percentage contents:<\/p>\n \u2014 for each impurity, use the concentration of escitalopram in reference solution (b) at 237 nm.<\/p>\n Limits:<\/p>\n \u2014 unspecified impurities at 237 nm and at 254 nm: for each impurity, maximum 0.10 per cent;<\/p>\n \u2014 total at 237 nm: maximum 0.5 per cent;<\/p>\n \u2014 reporting threshold at 237 nm: 0.05 per cent.<\/p>\n Enantiomeric purity<\/h3>\n Liquid chromatography (2.2.29): use the normalisation procedure.<\/p>\n Test solution: Dissolve 25.0 mg of the substance to be examined in the mobile phase and dilute to 50.0 mL with the mobile phase. Dilute 5.0 mL of the solution to 20.0 mL with the mobile phase.<\/p>\n Reference solution (a): Dissolve 5.0 mg of citalopram hydrobromide CRS (containing equal amounts of impurity K and escitalopram) in the mobile phase and dilute to 10.0 mL with the mobile phase. Dilute 5.0 mL of the solution to 20.0 mL with the mobile phase.<\/p>\n Reference solution (b): Dilute 1.0 mL of reference solution (a) to 50.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 10.0 mL with the mobile phase.<\/p>\n Column:<\/p>\n \u2014 size: l = 0.15 m, \u00d8 = 4.6 mm;<\/p>\n \u2014 stationary phase: protein derivative of silica gel for chiral separation R (5 \u03bcm);<\/p>\n \u2014 temperature: 30 \u00b0C.<\/p>\n Mobile phase acetonitrile R, 0.05 M phosphate buffer solution pH 7.0 R (15:85 V\/V).<\/p>\n Flow rate 0.6 mL\/min.<\/p>\n Detection: Spectrophotometer at 240 nm.<\/p>\n Injection 15 \u03bcL.<\/p>\n Run time Twice the retention time of escitalopram.<\/p>\n Identification of impurities: Use the chromatogram obtained with reference solution (a) to identify the peak due to impurity K.<\/p>\n Relative retention With reference to escitalopram (retention time = about 11 min): impurity K = about 1.2.<\/p>\n System suitability Reference solution (a):<\/p>\n \u2014 resolution: minimum 1.3 between the peaks due to escitalopram and impurity K;<\/p>\n \u2014 symmetry factor: maximum 4.0 for the peak due to escitalopram; maximum 4.0 for the peak due to impurity K.<\/p>\n Limits:<\/p>\n \u2014 impurity K: maximum 2.0 per cent;<\/p>\n \u2014 reporting threshold: 0.10 per cent (reference solution (b)).<\/p>\n Water (2.5.12)<\/h4>\n Maximum 0.2 per cent, determined on 0.500 g.<\/p>\n Sulfated ash (2.4.14)<\/h4>\n Maximum 0.1 per cent, determined on 1.0 g in a platinum crucible.<\/p>\n ASSAY<\/h2>\n Dissolve 0.300 g in a mixture of 5.0 mL of acetic anhydride R and 75 mL of glacial acetic acid R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20).<\/p>\n 1 mL of 0.1 M perchloric acid is equivalent to 32.44 mg of C_{20<\/sub>H_{21<\/sub>FN_{2<\/sub>O.<\/p>\n}}} IMPURITIES<\/h2>\n Specified impurities K.<\/p>\n Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) A, B, C, D, E, F, G, H, I, J, L, M.<\/p>\n $\"Escitalopram\"$ <\/p>\n A. (1RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carboxamide,<\/p>\n $\"Escitalopram\"$ <\/p>\n B. mixture of (1RS,3RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydro-2-benzofuran-5-carbonitrile and (1RS,3SR)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydro-2-benzofuran-5-carbonitrile,<\/p>\n $\"Escitalopram\"$ <\/p>\n C. (1RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3-oxo-1,3-dihydro-2-benzofuran-5-carbonitrile,<\/p>\n $\"Escitalopram\"$ <\/p>\n D. (1RS)-1-(4-fluorophenyl)-1-[3-(methylamino)propyl]-1,3-dihydro-2-benzofuran-5-carbonitrile,<\/p>\n $\"Escitalopram\"$ <\/p>\n E. (4RS)-4-[4-cyano-2-(hydroxymethyl)phenyl]-4-(4-fluorophenyl)-4-hydroxy-N,N-dimethylbutan-1-aminium,<\/p>\n $\"Escitalopram\"$ <\/p>\n F. (1RS)-1-[3-(dimethylamino)propyl]-1-hydroxy-1,3-dihydro-2-benzofuran-5-carbonitrile,<\/p>\n $\"Escitalopram\"$ <\/p>\n G. 4-(dimethylamino)-1-[(1RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-yl]butan-1-one,<\/p>\n $\"Escitalopram\"$ <\/p>\n H. 3-[(1RS)-5-cyano-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-1-yl]-N,N-dimethylpropan-1-amine N-oxide,<\/p>\n $\"Escitalopram\"$ <\/p>\n I. 4-[(1Z)-4-(dimethylamino)-1-(4-fluorophenyl)but-1-en-1-yl]-3-(hydroxymethyl)benzonitrile,<\/p>\n $\"Escitalopram\"$ <\/p>\n J. 4-methylbenzenesulfonic acid (p-toluenesulfonic acid),<\/p>\n $\"Escitalopram\"$ <\/p>\n K. (1R)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile,<\/p>\n $\"Escitalopram\"$ <\/p>\n L. (1RS)-1-[3-(dimethylamino)propyl]-1-phenyl-1,3-dihydro-2-benzofuran-5-carbonitrile,<\/p>\n $\"Escitalopram\"$ <\/p>\n M. (1RS)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carboxylic acid.<\/p>\n","protected":false},"excerpt":{"rendered":" (Ph. Eur. monograph 2758) C20H21FN2O 324.4 128196-01-0Escitalopram Action and use Selective serotonin reuptake inhibitor; antidepressant. DEFINITION (1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile. Content 99.0 per cent to 101.0 per cent (anhydrous substance). CHARACTERS Appearance White or yellowish, crystalline powder. Solubility Practically insoluble in water, freely soluble in anhydrous ethanol and in toluene. IDENTIFICATION A. Infrared absorption spectrophotometry (2.2.24). Comparison escitalopram…<\/p>\n","protected":false},"author":2,"featured_media":12373,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-12335","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/12335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=12335"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/12335\/revisions"}],"predecessor-version":[{"id":12375,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/12335\/revisions\/12375"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/12373"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=12335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=12335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=12335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Content<\/h3>\n99.0 per cent to 101.0 per cent (anhydrous substance).<\/p>\n

CHARACTERS<\/h2>\n

Appearance<\/h3>\nWhite or yellowish, crystalline powder.<\/p>\n

Solubility<\/h3>\nPractically insoluble in water, freely soluble in anhydrous ethanol and in toluene.<\/p>\n

IDENTIFICATION<\/h2>\nA. Infrared absorption spectrophotometry (2.2.24).<\/p>\nComparison escitalopram CRS.<\/p>\nB. Enantiomeric purity (see Tests).<\/p>\n

TESTS<\/h2>\n

Water (2.5.12)<\/h4>\nMaximum 0.2 per cent, determined on 0.500 g.<\/p>\n

Sulfated ash (2.4.14)<\/h4>\nMaximum 0.1 per cent, determined on 1.0 g in a platinum crucible.<\/p>\n

Content<\/h3>\n
99.0 per cent to 101.0 per cent (anhydrous substance).<\/p>\n

Appearance<\/h3>\n
White or yellowish, crystalline powder.<\/p>\n

Solubility<\/h3>\n
Practically insoluble in water, freely soluble in anhydrous ethanol and in toluene.<\/p>\n

IDENTIFICATION<\/h2>\n
A. Infrared absorption spectrophotometry (2.2.24).<\/p>\n
Comparison escitalopram CRS.<\/p>\n
B. Enantiomeric purity (see Tests).<\/p>\n

Water (2.5.12)<\/h4>\n
Maximum 0.2 per cent, determined on 0.500 g.<\/p>\n

Sulfated ash (2.4.14)<\/h4>\n
Maximum 0.1 per cent, determined on 1.0 g in a platinum crucible.<\/p>\n